Stock Ratings / Health Care / NNOX / financials

BFLY (38) PHG (58) GEHC (65) MIRA (48) ⌘ Pro Terminal →

NANO-X IMAGING LTD (NNOX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: Is NNOX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, NANO-X IMAGING LTD (NASDAQ: NNOX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.31 (-4.82% 1D, market cap $24.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NNOX ranks #898 in composite RQD confidence.

Q: How does NNOX compare to BFLY and PHG in the Health Care sector?

Within the Health Care sector (Medical Electronics), NNOX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, BFLY (Butterfly Network Inc. (Class A)) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.00B) and PHG (Koninklijke Philips N.V. NY Registry Shares) posts a D+ grade (58/100 RQD, P/E 32.8x, ROIC 9.9%, cap $26.66B). Among the 5-stock peer group, GEHC leads on earnings multiple (16.6x) while GEHC leads on capital efficiency (14.2% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for NNOX?

Per NNOX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001795251), NANO-X IMAGING LTD generated $13.0M in revenue (+15.4% YoY), -$75.0M in net income, and -$45.0M in free cash flow against $162.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is NNOX trading relative to its 50-day, 200-day, and 52-week technical levels?

NNOX last traded at $0.31 (-4.82% on volume of 1,250,165 shares), positioning the stock -50.79% below its 50-day simple moving average ($0.63) and -80.63% below its 200-day simple moving average ($1.60). Across its 52-week range of $0.28 to $4.71, NNOX sits at the 0.7% percentile with a 14-day RSI of 21.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.35).

Q: How profitable is NANO-X IMAGING LTD (NNOX)?

In FY 2025 (10-K), NNOX converted $13.0M of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

$0.31 -4.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.31

NANO-X IMAGING LTD (NNOX) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $24.0M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.31 (-1.06%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-12.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NNOX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY NNOX SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (38% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (25% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 21 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$0.54-16.7% Next Q

Q2 (-2Q)

Grade E$0.45-17.8% Next Q

Q3 (-1Q)

Grade E$0.37-16.2% Next Q

Current

Grade E$0.31-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NNOX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NNOX currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.63) and Max Pain ($0.33) forces dealer call-delta covering toward $4.95.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NNOX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NNOX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How NNOX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $9.9M

FY24

Rev $11.3M

FY25

Rev $13.0M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$13.0M	-50%	-80%	-$75.0M	-$45.0M	-45%
FY 2024	$11.3M	-50%	-80%	-$53.5M	-$39.4M	-29.9%
FY 2023	$9.9M	8%	-80%	-$60.8M	-$44.8M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NNOX)

✓Walkthrough of NNOX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NNOX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -81.87%▼ DESCENDING CHANNEL

2026-10-30O $0.30H $0.34L $0.29C $0.31VOL 933.0K

RES: $0.64SUP: $-0.10SMA50: $0.63SMA200: $1.60

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NNOX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NNOX Butterfly Map → + Track NNOX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NNOX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NNOX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NNOX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NNOX)

Health Care Rank #898 of 1016 ⚔️ BFLY vs NNOX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NNOX vs. BFLY, PHG, GEHC, MIRA)

Industry: Medical Electronics (4 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, NANO-X IMAGING LTD (NNOX) ranks #898 by composite RQD confidence (32/100, grade E) and #822 by equity capitalization ($24.0M). Within this direct 5-issuer industry benchmark cohort, GEHC leads on earnings valuation at 16.6x trailing P/E, while GEHC leads on capital efficiency and profitability with 14.2% ROIC and 40.0% gross margin. GEHC currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with NNOX at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NNOX ACTIVE NANO-X IMAGING LTD	E	32/100	—	-30.0%	-35.0%	-4.82%	$24.0M	Benchmark Subject
BFLY Butterfly Network Inc. (Class A)	D-	38/100	—	46.9%	-35.0%	-3.84%	$2.00B	/bfly-vs-nnox →
PHG Koninklijke Philips N.V. NY Registry Shares	D+	58/100	32.8x	—	9.9%	+0.33%	$26.66B	/phg-vs-nnox →
GEHC GE HealthCare Technologies Inc.	C	65/100	16.6x	40.0%	14.2%	+0.79%	$34.55B	/gehc-vs-nnox →
MIRA MIRA Pharmaceuticals Inc.	D	48/100	—	—	-35.0%	+2.79%	$24.0M	/mira-vs-nnox →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001795251

In its most recent audited fiscal period (FY2025, filed 2025-12-31), NANO-X IMAGING LTD (NNOX) reported GAAP revenue of $13.0M (+15.4% vs. FY2024 revenue of $11.3M , and +31.5% cumulative change since FY2023) , GAAP net income of -$75.0M, operating cash flow of -$40.8M, and free cash flow of -$45.0M (-14.3% YoY). On the balance sheet, NNOX closed FY2025 with $162.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$13.0M	-$75.0M	-$40.8M	-$45.0M	$162.2M	—
FY2024 (FY)	2024-12-31	$11.3M	-$53.5M	-$36.6M	-$39.4M	$210.0M	—
FY2023 (FY)	2023-12-31	$9.9M	-$60.8M	-$44.8M	-$44.8M	—	—

3. NNOX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NNOX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, NANO-X IMAGING LTD (NASDAQ: NNOX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.31 (-4.82% 1D, market cap $24.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NNOX ranks #898 in composite RQD confidence.

How does NNOX compare to BFLY and PHG in the Health Care sector?

Within the Health Care sector (Medical Electronics), NNOX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, BFLY (Butterfly Network Inc. (Class A)) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.00B) and PHG (Koninklijke Philips N.V. NY Registry Shares) posts a D+ grade (58/100 RQD, P/E 32.8x, ROIC 9.9%, cap $26.66B). Among the 5-stock peer group, GEHC leads on earnings multiple (16.6x) while GEHC leads on capital efficiency (14.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NNOX?

Per NNOX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001795251), NANO-X IMAGING LTD generated $13.0M in revenue (+15.4% YoY), -$75.0M in net income, and -$45.0M in free cash flow against $162.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NNOX trading relative to its 50-day, 200-day, and 52-week technical levels?

NNOX last traded at $0.31 (-4.82% on volume of 1,250,165 shares), positioning the stock -50.79% below its 50-day simple moving average ($0.63) and -80.63% below its 200-day simple moving average ($1.60). Across its 52-week range of $0.28 to $4.71, NNOX sits at the 0.7% percentile with a 14-day RSI of 21.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.35).

NNOX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is NANO-X IMAGING LTD (NNOX)?

In FY 2025 (10-K), NNOX converted $13.0M of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: NNOX RQD Cockpit NNOX 12M Forecast NNOX Earnings & Move NNOX Dividends & DRIP NNOX Insiders & 13F NNOX Whale Options NNOX Profit Sankey NNOX News & Why